speb/financial-data huggingface dataset:
ZYME balance_sheet (quarterly, 2025-09-30) — Current Deferred Liabilities: 3197000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Current Deferred Revenue: 3197000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 42043000.00
ZYME cash_flow (quarterly, 2025-09-30) — Deferred Income Tax: -170000.00
ZYME cash_flow (quarterly, 2025-09-30) — Deferred Tax: -170000.00
ZYME cash_flow (quarterly, 2025-09-30) — Depreciation: 1936000.00
ZYME cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 2584000.00
ZYME cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 2584000.00
ZYME income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 75775214.00
ZYME income_statement (quarterly, 2025-09-30) — Diluted EPS: -0.26
ZYME income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -19770000.00
ZYME income_statement (quarterly, 2025-09-30) — EBIT: -22064000.00
ZYME income_statement (quarterly, 2025-09-30) — EBITDA: -19480000.00
ZYME cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: 77000.00
ZYME cash_flow (quarterly, 2025-09-30) — End Cash Position: 64834000.00
ZYME cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -2452000.00
ZYME cash_flow (quarterly, 2025-09-30) — Free Cash Flow: -31822000.00
ZYME income_statement (quarterly, 2025-09-30) — Gain On Sale Of Security: 289000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: -6050000.00
ZYME income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 14100000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Goodwill: 12016000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 13413000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Gross PPE: 32467000.00
ZYME income_statement (quarterly, 2025-09-30) — Impairment Of Capital Assets: 0.00
ZYME cash_flow (quarterly, 2025-09-30) — Income Tax Paid Supplemental Data: 660000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Income Tax Payable: 1016000.00
ZYME income_statement (quarterly, 2025-09-30) — Interest Income: 3529000.00
ZYME income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 3529000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Invested Capital: 320064000.00
ZYME cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: 368000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 47427000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Investments And Advances: 47427000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 15504000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 15504000.00
ZYME cash_flow (quarterly, 2025-09-30) — Net Foreign Currency Exchange Gain Loss: -451000.00
ZYME income_statement (quarterly, 2025-09-30) — Net Income: -19602000.00
ZYME income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -19602000.00
ZYME income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -19602000.00
ZYME income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -19602000.00
ZYME income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -19602000.00
ZYME cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -19602000.00
ZYME income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -19602000.00
ZYME cash_flow (quarterly, 2025-09-30) — Net Intangibles Purchase And Sale: 0.00
ZYME income_statement (quarterly, 2025-09-30) — Net Interest Income: 3529000.00
ZYME cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: 778000.00
ZYME income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: 3529000.00
ZYME cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: -28000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Net PPE: 32467000.00
ZYME cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -410000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 306651000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Assets: 4862000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Liabilities: 19380000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Revenue: 14607000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 4862000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 4773000.00
ZYME income_statement (quarterly, 2025-09-30) — Normalized EBITDA: -19769000.00
ZYME income_statement (quarterly, 2025-09-30) — Normalized Income: -19830310.00
ZYME cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: -31412000.00
ZYME cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: -451000.00
ZYME income_statement (quarterly, 2025-09-30) — Operating Income: -22064000.00
ZYME income_statement (quarterly, 2025-09-30) — Operating Revenue: 27614000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 75708470.00
ZYME balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 10427000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 415000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: -6050000.00
ZYME income_statement (quarterly, 2025-09-30) — Other Gand A: 7400000.00
ZYME income_statement (quarterly, 2025-09-30) — Other Income Expense: 315000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 1397000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 7388000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 278000.00
ZYME income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 26000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Other Properties: 32467000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 187099000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Payables: 2321000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 30503000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Pensionand Other Post Retirement Benefit Plans Current: 4528000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Preferred Stock: 0.00
ZYME income_statement (quarterly, 2025-09-30) — Pretax Income: -18266000.00
ZYME cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: 8804000.00
ZYME cash_flow (quarterly, 2025-09-30) — Purchase Of Intangibles: 0.00
ZYME cash_flow (quarterly, 2025-09-30) — Purchase Of Investment: -35054000.00
ZYME cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -410000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Receivables: 29352000.00
ZYME income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 2584000.00
ZYME income_statement (quarterly, 2025-09-30) — Research And Development: 35578000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -886472000.00
ZYME income_statement (quarterly, 2025-09-30) — Salaries And Wages: 6700000.00
ZYME cash_flow (quarterly, 2025-09-30) — Sale Of Investment: 35832000.00
ZYME income_statement (quarterly, 2025-09-30) — Selling General And Administration: 14100000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Share Issued: 75708470.00
ZYME income_statement (quarterly, 2025-09-30) — Special Income Charges: 0.00
ZYME cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 6911000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 320064000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 306651000.00
ZYME income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 60690.00
ZYME income_statement (quarterly, 2025-09-30) — Tax Provision: 1336000.00
ZYME income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.21
ZYME balance_sheet (quarterly, 2025-09-30) — Total Assets: 397269000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 320064000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Total Debt: 18904000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 320064000.00
ZYME income_statement (quarterly, 2025-09-30) — Total Expenses: 49678000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 77205000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 105557000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 35162000.00
ZYME income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: -22110000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 1016000.00
ZYME income_statement (quarterly, 2025-09-30) — Total Unusual Items: 289000.00
ZYME income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 289000.00
ZYME balance_sheet (quarterly, 2025-09-30) — Working Capital: 249669000.00
ZYME income_statement (annual, 2025-12-31) — +Operating Expense: 198500000.00
ZYME income_statement (quarterly, 2025-12-31) — +Operating Expense: 46635000.00
ZYME income_statement (annual, 2025-12-31) — +Total Revenue: 105965000.00
ZYME income_statement (quarterly, 2025-12-31) — +Total Revenue: 2515000.00
ZYME balance_sheet (annual, 2025-12-31) — Accounts Payable: 4403000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 4403000.00
ZYME balance_sheet (annual, 2025-12-31) — Accounts Receivable: 4638000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 4638000.00
ZYME balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -20876000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -20876000.00
ZYME balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 114626000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 114626000.00
ZYME cash_flow (annual, 2025-12-31) — Amortization Cash Flow: 4056000.00
ZYME cash_flow (quarterly, 2025-12-31) — Amortization Cash Flow: 185000.00
ZYME cash_flow (annual, 2025-12-31) — Amortization Of Intangibles: 4056000.00
ZYME cash_flow (quarterly, 2025-12-31) — Amortization Of Intangibles: 185000.00
ZYME cash_flow (annual, 2025-12-31) — Asset Impairment Charge: 0.00
ZYME cash_flow (quarterly, 2025-12-31) — Asset Impairment Charge: 0.00
ZYME income_statement (annual, 2025-12-31) — Average Dilution Earnings: -196000.00
ZYME income_statement (quarterly, 2025-12-31) — Average Dilution Earnings: 149000.00
ZYME income_statement (annual, 2025-12-31) — Basic Average Shares: 75404897.00
ZYME income_statement (quarterly, 2025-12-31) — Basic Average Shares: 75337800.00
ZYME income_statement (annual, 2025-12-31) — Basic EPS: -1.08
ZYME income_statement (quarterly, 2025-12-31) — Basic EPS: -0.55
ZYME cash_flow (annual, 2025-12-31) — Beginning Cash Position: 66103000.00
ZYME cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 64834000.00
ZYME cash_flow (annual, 2025-12-31) — Capital Expenditure: -2352000.00
ZYME cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -720000.00
ZYME balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 18267000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 18267000.00
ZYME balance_sheet (annual, 2025-12-31) — Capital Stock: 1113114000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Capital Stock: 1113114000.00
ZYME balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 41157000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 41157000.00
ZYME balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 228797000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 228797000.00
ZYME balance_sheet (annual, 2025-12-31) — Cash Equivalents: 32189000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Cash Equivalents: 32189000.00
ZYME balance_sheet (annual, 2025-12-31) — Cash Financial: 8968000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Cash Financial: 8968000.00
ZYME cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: -18559000.00
ZYME cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: -18742000.00
ZYME cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: 26663000.00
ZYME cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: 5368000.00
ZYME cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: -33005000.00
ZYME cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: -10259000.00
ZYME cash_flow (annual, 2025-12-31) — Change In Account Payable: -23648000.00
ZYME cash_flow (quarterly, 2025-12-31) — Change In Account Payable: 1335000.00
ZYME cash_flow (annual, 2025-12-31) — Change In Income Tax Payable: -45000.00
ZYME cash_flow (quarterly, 2025-12-31) — Change In Income Tax Payable: -933000.00
ZYME cash_flow (annual, 2025-12-31) — Change In Other Current Liabilities: -3342000.00
ZYME cash_flow (quarterly, 2025-12-31) — Change In Other Current Liabilities: -838000.00
ZYME cash_flow (annual, 2025-12-31) — Change In Other Working Capital: -23170000.00
ZYME cash_flow (quarterly, 2025-12-31) — Change In Other Working Capital: -779000.00
ZYME cash_flow (annual, 2025-12-31) — Change In Payable: -23693000.00
ZYME cash_flow (quarterly, 2025-12-31) — Change In Payable: 402000.00
ZYME cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: -23693000.00
ZYME cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 402000.00
ZYME cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: 6509000.00
ZYME cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: -5120000.00
ZYME cash_flow (annual, 2025-12-31) — Change In Receivables: 51200000.00
ZYME cash_flow (quarterly, 2025-12-31) — Change In Receivables: 24713000.00
ZYME cash_flow (annual, 2025-12-31) — Change In Tax Payable: -45000.00
ZYME cash_flow (quarterly, 2025-12-31) — Change In Tax Payable: -933000.00
ZYME cash_flow (annual, 2025-12-31) — Change In Working Capital: 7504000.00
ZYME cash_flow (quarterly, 2025-12-31) — Change In Working Capital: 18378000.00
ZYME cash_flow (annual, 2025-12-31) — Changes In Account Receivables: 51200000.00
ZYME cash_flow (quarterly, 2025-12-31) — Changes In Account Receivables: 24713000.00
ZYME cash_flow (annual, 2025-12-31) — Changes In Cash: -24901000.00
ZYME cash_flow (quarterly, 2025-12-31) — Changes In Cash: -23633000.00
ZYME balance_sheet (annual, 2025-12-31) — Common Stock: 1113114000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Common Stock: 1113114000.00
ZYME balance_sheet (annual, 2025-12-31) — Common Stock Equity: 268501000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 268501000.00
ZYME cash_flow (annual, 2025-12-31) — Common Stock Issuance: 4988000.00
ZYME cash_flow (quarterly, 2025-12-31) — Common Stock Issuance: 0.00
ZYME cash_flow (annual, 2025-12-31) — Common Stock Payments: -41695000.00
ZYME cash_flow (quarterly, 2025-12-31) — Common Stock Payments: -25479000.00
ZYME balance_sheet (annual, 2025-12-31) — Construction In Progress: 540000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Construction In Progress: 540000.00
ZYME balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 21846000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 21846000.00
ZYME balance_sheet (annual, 2025-12-31) — Current Assets: 248767000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Current Assets: 248767000.00
ZYME balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 3471000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 3471000.00
ZYME balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 3471000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 3471000.00
ZYME balance_sheet (annual, 2025-12-31) — Current Deferred Liabilities: 2418000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Current Deferred Liabilities: 2418000.00
ZYME balance_sheet (annual, 2025-12-31) — Current Deferred Revenue: 2418000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Current Deferred Revenue: 2418000.00
ZYME balance_sheet (annual, 2025-12-31) — Current Liabilities: 42318000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 42318000.00
ZYME cash_flow (annual, 2025-12-31) — Deferred Income Tax: 945000.00
ZYME cash_flow (quarterly, 2025-12-31) — Deferred Income Tax: 1410000.00
ZYME cash_flow (annual, 2025-12-31) — Deferred Tax: 945000.00
ZYME cash_flow (quarterly, 2025-12-31) — Deferred Tax: 1410000.00
ZYME cash_flow (annual, 2025-12-31) — Depreciation: 7054000.00
ZYME cash_flow (quarterly, 2025-12-31) — Depreciation: 1822000.00
ZYME cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 11110000.00
ZYME cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 2007000.00
ZYME cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 11110000.00
ZYME cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 2007000.00
ZYME income_statement (annual, 2025-12-31) — Diluted Average Shares: 75413396.00
ZYME income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 75337800.00
ZYME income_statement (annual, 2025-12-31) — Diluted EPS: -1.08
ZYME income_statement (quarterly, 2025-12-31) — Diluted EPS: -0.55
ZYME income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: -81326000.00
ZYME income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -41060000.00
ZYME income_statement (annual, 2025-12-31) — EBIT: -92535000.00
ZYME income_statement (quarterly, 2025-12-31) — EBIT: -44120000.00
ZYME income_statement (annual, 2025-12-31) — EBITDA: -81425000.00
ZYME income_statement (quarterly, 2025-12-31) — EBITDA: -42113000.00
ZYME cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: -45000.00
ZYME cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: -44000.00
ZYME cash_flow (annual, 2025-12-31) — End Cash Position: 41157000.00
ZYME cash_flow (quarterly, 2025-12-31) — End Cash Position: 41157000.00
ZYME cash_flow (annual, 2025-12-31) — Financing Cash Flow: -18559000.00
ZYME cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: -18742000.00
ZYME cash_flow (annual, 2025-12-31) — Free Cash Flow: -35357000.00
ZYME cash_flow (quarterly, 2025-12-31) — Free Cash Flow: -10979000.00
ZYME income_statement (annual, 2025-12-31) — Gain On Sale Of Security: -610000.00
ZYME income_statement (quarterly, 2025-12-31) — Gain On Sale Of Security: -284000.00
ZYME balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -6079000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -6079000.00
ZYME income_statement (annual, 2025-12-31) — General And Administrative Expense: 61500000.00
ZYME income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 15400000.00
ZYME balance_sheet (annual, 2025-12-31) — Goodwill: 12016000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Goodwill: 12016000.00
ZYME balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 13366000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 13366000.00
ZYME balance_sheet (annual, 2025-12-31) — Gross PPE: 52102000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Gross PPE: 52102000.00
ZYME income_statement (annual, 2025-12-31) — Impairment Of Capital Assets: 0.00
ZYME income_statement (quarterly, 2025-12-31) — Impairment Of Capital Assets: 0.00
ZYME cash_flow (annual, 2025-12-31) — Income Tax Paid Supplemental Data: 1350000.00
ZYME cash_flow (quarterly, 2025-12-31) — Income Tax Paid Supplemental Data: 107000.00
ZYME balance_sheet (annual, 2025-12-31) — Income Tax Payable: 83000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Income Tax Payable: 83000.00
ZYME income_statement (annual, 2025-12-31) — Interest Income: 13354000.00
ZYME income_statement (quarterly, 2025-12-31) — Interest Income: 2975000.00
ZYME income_statement (annual, 2025-12-31) — Interest Income Non Operating: 13354000.00
ZYME income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: 2975000.00
ZYME balance_sheet (annual, 2025-12-31) — Invested Capital: 268501000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Invested Capital: 268501000.00
ZYME cash_flow (annual, 2025-12-31) — Investing Cash Flow: 26663000.00
ZYME cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: 5368000.00
ZYME balance_sheet (annual, 2025-12-31) — Investments And Advances: 41787000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Investments And Advances: 41787000.00
ZYME cash_flow (annual, 2025-12-31) — Issuance Of Capital Stock: 4988000.00
ZYME cash_flow (quarterly, 2025-12-31) — Issuance Of Capital Stock: 0.00
ZYME balance_sheet (annual, 2025-12-31) — Leases: 15243000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Leases: 15243000.00
ZYME balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 14796000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 14796000.00
ZYME balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 14796000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 14796000.00
ZYME balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 6757000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 6757000.00
ZYME cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: -36707000.00
ZYME cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: -25479000.00
ZYME cash_flow (annual, 2025-12-31) — Net Foreign Currency Exchange Gain Loss: 532000.00
ZYME cash_flow (quarterly, 2025-12-31) — Net Foreign Currency Exchange Gain Loss: 305000.00
ZYME income_statement (annual, 2025-12-31) — Net Income: -81130000.00
ZYME income_statement (quarterly, 2025-12-31) — Net Income: -41209000.00
ZYME income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -81130000.00
ZYME income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -41209000.00
ZYME income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -81130000.00
ZYME income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -41209000.00
ZYME income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -81130000.00
ZYME income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -41209000.00
ZYME income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -81130000.00
ZYME income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -41209000.00
ZYME cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: -81130000.00
ZYME cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -41209000.00
ZYME income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -81130000.00
ZYME income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -41209000.00
ZYME cash_flow (annual, 2025-12-31) — Net Intangibles Purchase And Sale: -831000.00
ZYME cash_flow (quarterly, 2025-12-31) — Net Intangibles Purchase And Sale: -139000.00
ZYME income_statement (annual, 2025-12-31) — Net Interest Income: 13354000.00
ZYME income_statement (quarterly, 2025-12-31) — Net Interest Income: 2975000.00
ZYME cash_flow (annual, 2025-12-31) — Net Investment Purchase And Sale: 29015000.00
ZYME cash_flow (quarterly, 2025-12-31) — Net Investment Purchase And Sale: 6088000.00
ZYME income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: 13354000.00
ZYME income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: 2975000.00
ZYME cash_flow (annual, 2025-12-31) — Net Other Financing Charges: -181000.00
ZYME cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: -88000.00
ZYME balance_sheet (annual, 2025-12-31) — Net PPE: 31226000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Net PPE: 31226000.00
ZYME cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -1521000.00
ZYME cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: -581000.00
ZYME balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 255135000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 255135000.00
ZYME balance_sheet (annual, 2025-12-31) — Non Current Deferred Assets: 4707000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Assets: 4707000.00
ZYME balance_sheet (annual, 2025-12-31) — Non Current Deferred Liabilities: 20634000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Liabilities: 20634000.00
ZYME balance_sheet (annual, 2025-12-31) — Non Current Deferred Revenue: 14606000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Revenue: 14606000.00
ZYME balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Assets: 4707000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Assets: 4707000.00
ZYME balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Liabilities: 6028000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 6028000.00
ZYME income_statement (annual, 2025-12-31) — Normalized EBITDA: -80815000.00
ZYME income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -41829000.00
ZYME income_statement (annual, 2025-12-31) — Normalized Income: -80648100.00
ZYME income_statement (quarterly, 2025-12-31) — Normalized Income: -40926848.65
ZYME cash_flow (annual, 2025-12-31) — Operating Cash Flow: -33005000.00
ZYME cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: -10259000.00
ZYME cash_flow (annual, 2025-12-31) — Operating Gains Losses: 532000.00
ZYME cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: 305000.00
ZYME income_statement (annual, 2025-12-31) — Operating Income: -92535000.00
ZYME income_statement (quarterly, 2025-12-31) — Operating Income: -44120000.00
ZYME income_statement (annual, 2025-12-31) — Operating Revenue: 105965000.00
ZYME income_statement (quarterly, 2025-12-31) — Operating Revenue: 2515000.00
ZYME balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 75191597.00
ZYME balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 75191597.00
ZYME balance_sheet (annual, 2025-12-31) — Other Current Assets: 15332000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Other Current Assets: 15332000.00
ZYME balance_sheet (annual, 2025-12-31) — Other Current Liabilities: 844000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Other Current Liabilities: 844000.00
ZYME balance_sheet (annual, 2025-12-31) — Other Equity Adjustments: -6079000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Other Equity Adjustments: -6079000.00
ZYME income_statement (annual, 2025-12-31) — Other Gand A: 30600000.00
ZYME income_statement (quarterly, 2025-12-31) — Other Gand A: 5900000.00
ZYME income_statement (annual, 2025-12-31) — Other Income Expense: -559000.00
ZYME income_statement (quarterly, 2025-12-31) — Other Income Expense: -302000.00
ZYME balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 1350000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 1350000.00
ZYME balance_sheet (annual, 2025-12-31) — Other Non Current Assets: 6674000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Other Non Current Assets: 6674000.00
ZYME balance_sheet (annual, 2025-12-31) — Other Non Current Liabilities: 278000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Other Non Current Liabilities: 278000.00
ZYME income_statement (annual, 2025-12-31) — Other Non Operating Income Expenses: 51000.00
ZYME income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: -18000.00
ZYME balance_sheet (annual, 2025-12-31) — Other Properties: 29562000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Other Properties: 29562000.00
ZYME balance_sheet (annual, 2025-12-31) — Other Short Term Investments: 187640000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Other Short Term Investments: 187640000.00
ZYME balance_sheet (annual, 2025-12-31) — Payables: 4911000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Payables: 4911000.00
ZYME balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 26757000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 26757000.00
ZYME balance_sheet (annual, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 8828000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 8828000.00
ZYME balance_sheet (annual, 2025-12-31) — Preferred Stock: 0.00
ZYME balance_sheet (quarterly, 2025-12-31) — Preferred Stock: 0.00
ZYME income_statement (annual, 2025-12-31) — Pretax Income: -79754000.00
ZYME income_statement (quarterly, 2025-12-31) — Pretax Income: -41479000.00
ZYME cash_flow (annual, 2025-12-31) — Proceeds From Stock Option Exercised: 18329000.00
ZYME cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 6825000.00
ZYME balance_sheet (annual, 2025-12-31) — Properties: 0.00
ZYME balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
ZYME cash_flow (annual, 2025-12-31) — Purchase Of Intangibles: -831000.00
ZYME cash_flow (quarterly, 2025-12-31) — Purchase Of Intangibles: -139000.00
ZYME cash_flow (annual, 2025-12-31) — Purchase Of Investment: -196061000.00
ZYME cash_flow (quarterly, 2025-12-31) — Purchase Of Investment: -56828000.00
ZYME cash_flow (annual, 2025-12-31) — Purchase Of PPE: -1521000.00
ZYME cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: -581000.00
ZYME balance_sheet (annual, 2025-12-31) — Receivables: 4638000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Receivables: 4638000.00
ZYME income_statement (annual, 2025-12-31) — Reconciled Depreciation: 11110000.00
ZYME income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 2007000.00
ZYME cash_flow (annual, 2025-12-31) — Repurchase Of Capital Stock: -41695000.00
ZYME cash_flow (quarterly, 2025-12-31) — Repurchase Of Capital Stock: -25479000.00
ZYME income_statement (annual, 2025-12-31) — Research And Development: 137000000.00
ZYME income_statement (quarterly, 2025-12-31) — Research And Development: 31235000.00
ZYME balance_sheet (annual, 2025-12-31) — Retained Earnings: -953160000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -953160000.00
ZYME income_statement (annual, 2025-12-31) — Salaries And Wages: 30900000.00
ZYME income_statement (quarterly, 2025-12-31) — Salaries And Wages: 9500000.00
ZYME cash_flow (annual, 2025-12-31) — Sale Of Investment: 225076000.00
ZYME cash_flow (quarterly, 2025-12-31) — Sale Of Investment: 62916000.00
ZYME income_statement (annual, 2025-12-31) — Selling General And Administration: 61500000.00
ZYME income_statement (quarterly, 2025-12-31) — Selling General And Administration: 15400000.00
ZYME balance_sheet (annual, 2025-12-31) — Share Issued: 75191597.00
ZYME balance_sheet (quarterly, 2025-12-31) — Share Issued: 75191597.00
ZYME income_statement (annual, 2025-12-31) — Special Income Charges: 0.00
ZYME income_statement (quarterly, 2025-12-31) — Special Income Charges: 0.00
ZYME cash_flow (annual, 2025-12-31) — Stock Based Compensation: 28034000.00
ZYME cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 8850000.00
ZYME balance_sheet (annual, 2025-12-31) — Stockholders Equity: 268501000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 268501000.00
ZYME balance_sheet (annual, 2025-12-31) — Tangible Book Value: 255135000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 255135000.00
ZYME income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: -128100.00
ZYME income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -1848.65
ZYME income_statement (annual, 2025-12-31) — Tax Provision: 1376000.00
ZYME income_statement (quarterly, 2025-12-31) — Tax Provision: -270000.00
ZYME income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.21
ZYME income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.01
ZYME balance_sheet (annual, 2025-12-31) — Total Assets: 346527000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Total Assets: 346527000.00
ZYME balance_sheet (annual, 2025-12-31) — Total Capitalization: 268501000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 268501000.00
ZYME balance_sheet (annual, 2025-12-31) — Total Debt: 18267000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Total Debt: 18267000.00
ZYME balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 268501000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 268501000.00
ZYME income_statement (annual, 2025-12-31) — Total Expenses: 198500000.00
ZYME income_statement (quarterly, 2025-12-31) — Total Expenses: 46635000.00
ZYME balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 78026000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 78026000.00
ZYME balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 97760000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 97760000.00
ZYME balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 35708000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 35708000.00
ZYME income_statement (annual, 2025-12-31) — Total Operating Income As Reported: -92549000.00
ZYME income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: -44152000.00
ZYME balance_sheet (annual, 2025-12-31) — Total Tax Payable: 508000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Total Tax Payable: 508000.00
ZYME income_statement (annual, 2025-12-31) — Total Unusual Items: -610000.00
ZYME income_statement (quarterly, 2025-12-31) — Total Unusual Items: -284000.00
ZYME income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: -610000.00
ZYME income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -284000.00
ZYME cash_flow (annual, 2025-12-31) — Unrealized Gain Loss On Investment Securities: 0.00
ZYME balance_sheet (annual, 2025-12-31) — Working Capital: 206449000.00
ZYME balance_sheet (quarterly, 2025-12-31) — Working Capital: 206449000.00
ZYME income_statement (quarterly, 2026-03-31) — +Operating Expense: 49557000.00
ZYME income_statement (quarterly, 2026-03-31) — +Total Revenue: 2408000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 30226000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 4674000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 107530000.00
ZYME cash_flow (quarterly, 2026-03-31) — Amortization Cash Flow: 176000.00
ZYME cash_flow (quarterly, 2026-03-31) — Amortization Of Intangibles: 176000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 39116000.00
ZYME income_statement (quarterly, 2026-03-31) — Average Dilution Earnings: -60000.00
ZYME income_statement (quarterly, 2026-03-31) — Basic Average Shares: 74668790.00
ZYME income_statement (quarterly, 2026-03-31) — Basic EPS: -0.59
ZYME cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 41157000.00
ZYME cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -216000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 17042000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Capital Stock: 1136458000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 244282000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 364727000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Cash Equivalents: 178416000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Cash Financial: 65866000.00
ZYME cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: 178786000.00
ZYME cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: 69959000.00
ZYME cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -45718000.00
ZYME cash_flow (quarterly, 2026-03-31) — Change In Account Payable: -7750000.00
ZYME cash_flow (quarterly, 2026-03-31) — Change In Income Tax Payable: -16000.00
ZYME cash_flow (quarterly, 2026-03-31) — Change In Other Current Liabilities: -1005000.00
ZYME cash_flow (quarterly, 2026-03-31) — Change In Other Working Capital: -340000.00
ZYME cash_flow (quarterly, 2026-03-31) — Change In Payable: -7766000.00
ZYME cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: -7766000.00
ZYME cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: -1726000.00
ZYME cash_flow (quarterly, 2026-03-31) — Change In Receivables: -36000.00
ZYME cash_flow (quarterly, 2026-03-31) — Change In Tax Payable: -16000.00
ZYME cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -10873000.00
ZYME cash_flow (quarterly, 2026-03-31) — Changes In Account Receivables: -36000.00
ZYME cash_flow (quarterly, 2026-03-31) — Changes In Cash: 203027000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Common Stock: 1136458000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 163589000.00
ZYME cash_flow (quarterly, 2026-03-31) — Common Stock Issuance: 250000000.00
ZYME cash_flow (quarterly, 2026-03-31) — Common Stock Payments: -76151000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Current Assets: 385680000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 3279000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 3279000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Current Deferred Liabilities: 2078000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Current Deferred Revenue: 2078000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 35649000.00
ZYME cash_flow (quarterly, 2026-03-31) — Deferred Income Tax: -2200000.00
ZYME cash_flow (quarterly, 2026-03-31) — Deferred Tax: -2200000.00
ZYME cash_flow (quarterly, 2026-03-31) — Depreciation: 2671000.00
ZYME cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 2847000.00
ZYME cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 2847000.00
ZYME income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 74694762.00
ZYME income_statement (quarterly, 2026-03-31) — Diluted EPS: -0.59
ZYME income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -44222000.00
ZYME income_statement (quarterly, 2026-03-31) — EBIT: -44287000.00
ZYME income_statement (quarterly, 2026-03-31) — EBITDA: -41440000.00
ZYME cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: 98000.00
ZYME cash_flow (quarterly, 2026-03-31) — End Cash Position: 244282000.00
ZYME cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 178786000.00
ZYME cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -45934000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: -6565000.00
ZYME income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 15100000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Goodwill: 12016000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 13190000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Gross PPE: 28870000.00
ZYME cash_flow (quarterly, 2026-03-31) — Income Tax Paid Supplemental Data: 245000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Income Tax Payable: 66000.00
ZYME income_statement (quarterly, 2026-03-31) — Interest Expense: 2066000.00
ZYME income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 2066000.00
ZYME income_statement (quarterly, 2026-03-31) — Interest Income: 2711000.00
ZYME income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 2711000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Invested Capital: 163589000.00
ZYME cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: 69959000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 39116000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Investments And Advances: 39116000.00
ZYME cash_flow (quarterly, 2026-03-31) — Issuance Of Capital Stock: 250000000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 13763000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 13763000.00
ZYME cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: 173849000.00
ZYME cash_flow (quarterly, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: -331000.00
ZYME income_statement (quarterly, 2026-03-31) — Net Income: -44162000.00
ZYME income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -44162000.00
ZYME income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -44162000.00
ZYME income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -44162000.00
ZYME income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -44162000.00
ZYME cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -44162000.00
ZYME income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -44162000.00
ZYME cash_flow (quarterly, 2026-03-31) — Net Intangibles Purchase And Sale: 0.00
ZYME income_statement (quarterly, 2026-03-31) — Net Interest Income: 645000.00
ZYME cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: 70175000.00
ZYME income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: 645000.00
ZYME cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: -4387000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Net PPE: 28870000.00
ZYME cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: -216000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 150399000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Assets: 4707000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Liabilities: 18433000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Revenue: 14606000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 4707000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 3827000.00
ZYME income_statement (quarterly, 2026-03-31) — Normalized EBITDA: -41440000.00
ZYME income_statement (quarterly, 2026-03-31) — Normalized Income: -44162000.00
ZYME cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -45718000.00
ZYME cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: -331000.00
ZYME income_statement (quarterly, 2026-03-31) — Operating Income: -47149000.00
ZYME income_statement (quarterly, 2026-03-31) — Operating Revenue: 2408000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 73653573.00
ZYME balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 16279000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: -6565000.00
ZYME income_statement (quarterly, 2026-03-31) — Other Gand A: 5900000.00
ZYME income_statement (quarterly, 2026-03-31) — Other Income Expense: 120000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 1174000.00
ZYME cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: 2066000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 6652000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 246781000.00
ZYME income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 120000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Other Properties: 28870000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 120445000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Payables: 30292000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 30292000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Preferred Stock: 0.00
ZYME income_statement (quarterly, 2026-03-31) — Pretax Income: -46353000.00
ZYME cash_flow (quarterly, 2026-03-31) — Proceeds From Stock Option Exercised: 9324000.00
ZYME cash_flow (quarterly, 2026-03-31) — Purchase Of Intangibles: 0.00
ZYME cash_flow (quarterly, 2026-03-31) — Purchase Of Investment: 0.00
ZYME cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -216000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Receivables: 4674000.00
ZYME income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 2847000.00
ZYME cash_flow (quarterly, 2026-03-31) — Repurchase Of Capital Stock: -76151000.00
ZYME income_statement (quarterly, 2026-03-31) — Research And Development: 34457000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -1073834000.00
ZYME income_statement (quarterly, 2026-03-31) — Salaries And Wages: 9200000.00
ZYME cash_flow (quarterly, 2026-03-31) — Sale Of Investment: 70175000.00
ZYME income_statement (quarterly, 2026-03-31) — Selling General And Administration: 15100000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Share Issued: 73653573.00
ZYME cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 6935000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 163589000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 150399000.00
ZYME income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
ZYME income_statement (quarterly, 2026-03-31) — Tax Provision: -2191000.00
ZYME income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.05
ZYME balance_sheet (quarterly, 2026-03-31) — Total Assets: 478215000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 163589000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Total Debt: 17042000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 163589000.00
ZYME income_statement (quarterly, 2026-03-31) — Total Expenses: 49557000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 314626000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 92535000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 278977000.00
ZYME income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: -47118000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 66000.00
ZYME balance_sheet (quarterly, 2026-03-31) — Working Capital: 350031000.00
ZYNS.TO income_statement (annual, 2021-12-31) — Amortization: 96000000.00
ZYNS.TO income_statement (annual, 2021-12-31) — Amortization Of Intangibles Income Statement: 96000000.00
ZYNS.TO cash_flow (annual, 2021-12-31) — Change In Income Tax Payable: -260000000.00
ZYNS.TO cash_flow (annual, 2021-12-31) — Change In Tax Payable: -260000000.00
ZYNS.TO cash_flow (annual, 2021-12-31) — Common Stock Payments: -775000000.00
ZYNS.TO income_statement (annual, 2021-12-31) — Depreciation Amortization Depletion Income Statement: 96000000.00
ZYNS.TO income_statement (annual, 2021-12-31) — Depreciation And Amortization In Income Statement: 96000000.00
ZYNS.TO income_statement (annual, 2021-12-31) — General And Administrative Expense: 8400000000.00
ZYNS.TO cash_flow (annual, 2021-12-31) — Net Common Stock Issuance: -775000000.00
ZYNS.TO income_statement (annual, 2021-12-31) — Other Gand A: 8400000000.00
ZYNS.TO cash_flow (annual, 2021-12-31) — Purchase Of Business: -2111000000.00
ZYNS.TO cash_flow (annual, 2021-12-31) — Repurchase Of Capital Stock: -775000000.00
ZYNS.TO income_statement (annual, 2021-12-31) — Salaries And Wages: 115000000.00
ZYNS.TO income_statement (annual, 2021-12-31) — Selling And Marketing Expense: 8304000000.00
ZYNS.TO balance_sheet (annual, 2021-12-31) — Tradeand Other Payables Non Current: 1766000000.00
ZYNS.TO income_statement (annual, 2022-12-31) — +Operating Expense: 8114000000.00
ZYNS.TO income_statement (annual, 2022-12-31) — +Total Revenue: 31762000000.00
ZYNS.TO balance_sheet (annual, 2022-12-31) — Accounts Payable: 4076000000.00
ZYNS.TO balance_sheet (annual, 2022-12-31) — Accounts Receivable: 3850000000.00
ZYNS.TO balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -8733000000.00
ZYNS.TO balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 2230000000.00